Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Director · President, COO & Interim CEO | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bicara Therapeutics Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 181,641 |
Ending reported balance
After 2026-09-08 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-08 · Exercise / conversion · Acquired 17,500 · Balance 199,141 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Row 2 · 2026-09-08 · Sale · Disposed 14,058 · Balance 185,083 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.26 to $23.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 3 · 2026-09-08 · Sale · Disposed 3,442 · Balance 181,641 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.26 to $23.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79 · Expires 2033-04-05 | Direct | 34,252 |
Reported balance
After 2026-09-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-08 · Exercise / conversion · Disposed 17,500 · Balance 34,252 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F4: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.26 to $23.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.26 to $23.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F4: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 20:23 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001470831-26-000883 · wk-form4_1789071782.xml · derivative · entry 4 Cohlhepp Ryan · CIK 0002034665 · Director · President, COO & Interim CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,252 Underlying: Common Stock · 17,500 shares Expires 2033-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F4 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:23 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 3,442 | $23.43 | $80,662.93 |
DisclosureSEC source: 0001470831-26-000883 · wk-form4_1789071782.xml · nonDerivative · entry 3 Cohlhepp Ryan · CIK 0002034665 · Director · President, COO & Interim CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,641 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.26 to $23.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:23 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 14,058 | $22.77 | $320,052.86 |
DisclosureSEC source: 0001470831-26-000883 · wk-form4_1789071782.xml · nonDerivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President, COO & Interim CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,083 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.26 to $23.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:23 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 17,500 | $3.79 | $66,321.50 |
DisclosureSEC source: 0001470831-26-000883 · wk-form4_1789071782.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President, COO & Interim CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 199,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:19 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,750 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001470831-26-000812 · wk-form4_1786565947.xml · derivative · entry 3 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,752 Underlying: Common Stock · 18,750 shares Expires 2033-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:19 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 18,750 | $27.98 | $524,533.13 |
DisclosureSEC source: 0001470831-26-000812 · wk-form4_1786565947.xml · nonDerivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,641 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.56 to $28.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:19 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 18,750 | $3.79 | $71,058.75 |
DisclosureSEC source: 0001470831-26-000812 · wk-form4_1786565947.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 20:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 536 | $29.00 | $15,544.00 |
DisclosureSEC source: 0001470831-26-000701 · wk-form4_1783714248.xml · nonDerivative · entry 5 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,641 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,750 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001470831-26-000701 · wk-form4_1783714248.xml · derivative · entry 6 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,502 Underlying: Common Stock · 18,750 shares Expires 2033-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F5 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 1,075 | $30.35 | $32,631.52 |
DisclosureSEC source: 0001470831-26-000701 · wk-form4_1783714248.xml · nonDerivative · entry 4 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,177 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.25 to $30.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 4,306 | $29.80 | $128,302.01 |
DisclosureSEC source: 0001470831-26-000701 · wk-form4_1783714248.xml · nonDerivative · entry 3 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,252 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.23 to $30.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 22,833 | $28.76 | $656,651.96 |
DisclosureSEC source: 0001470831-26-000701 · wk-form4_1783714248.xml · nonDerivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,558 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.21 to $29.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 18,750 | $3.79 | $71,058.75 |
DisclosureSEC source: 0001470831-26-000701 · wk-form4_1783714248.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:24 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-035937 · wk-form4_1779135854.xml · derivative · entry 4 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,334 Underlying: Common Stock · 8,000 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:24 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 4,500 | $20.29 | $91,313.55 |
DisclosureSEC source: 0001628280-26-035937 · wk-form4_1779135854.xml · nonDerivative · entry 3 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,641 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.08 to $20.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:24 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 8,000 | $20.29 | $162,335.20 |
DisclosureSEC source: 0001628280-26-035937 · wk-form4_1779135854.xml · nonDerivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,141 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.08 to $20.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:24 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 8,000 | $3.79 | $30,318.40 |
DisclosureSEC source: 0001628280-26-035937 · wk-form4_1779135854.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:55 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-025817 · wk-form4_1776459315.xml · derivative · entry 4 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,334 Underlying: Common Stock · 8,000 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:55 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 4,500 | $23.01 | $103,532.85 |
DisclosureSEC source: 0001628280-26-025817 · wk-form4_1776459315.xml · nonDerivative · entry 3 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,141 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.58 to $23.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:55 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 8,000 | $23.01 | $184,058.40 |
DisclosureSEC source: 0001628280-26-025817 · wk-form4_1776459315.xml · nonDerivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,641 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.58 to $23.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:55 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 8,000 | $3.79 | $30,318.40 |
DisclosureSEC source: 0001628280-26-025817 · wk-form4_1776459315.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:36 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-018934 · wk-form4_1773783415.xml · derivative · entry 4 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,334 Underlying: Common Stock · 8,000 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:36 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 4,500 | $19.66 | $88,456.95 |
DisclosureSEC source: 0001628280-26-018934 · wk-form4_1773783415.xml · nonDerivative · entry 3 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,641 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.34 to $19.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:36 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 8,000 | $19.66 | $157,256.80 |
DisclosureSEC source: 0001628280-26-018934 · wk-form4_1773783415.xml · nonDerivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,141 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.34 to $19.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:36 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 8,000 | $3.79 | $30,318.40 |
DisclosureSEC source: 0001628280-26-018934 · wk-form4_1773783415.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,892 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-015423 · wk-form4_1772755827.xml · derivative · entry 4 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,334 Underlying: Common Stock · 12,892 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 4,500 | $18.16 | $81,733.95 |
DisclosureSEC source: 0001628280-26-015423 · wk-form4_1772755827.xml · nonDerivative · entry 3 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,141 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 12,892 | $18.16 | $234,158.69 |
DisclosureSEC source: 0001628280-26-015423 · wk-form4_1772755827.xml · nonDerivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,641 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:10 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 12,892 | $3.79 | $48,858.10 |
DisclosureSEC source: 0001628280-26-015423 · wk-form4_1772755827.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:13 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,108 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-012823 · wk-form4_1772226833.xml · derivative · entry 4 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,226 Underlying: Common Stock · 3,108 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:13 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 523 | $18.04 | $9,434.66 |
DisclosureSEC source: 0001628280-26-012823 · wk-form4_1772226833.xml · nonDerivative · entry 3 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,641 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:13 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 3,108 | $18.04 | $56,066.77 |
DisclosureSEC source: 0001628280-26-012823 · wk-form4_1772226833.xml · nonDerivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,164 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:13 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 3,108 | $3.79 | $11,778.70 |
DisclosureSEC source: 0001628280-26-012823 · wk-form4_1772226833.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:38 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $16.76 | $0.00 |
DisclosureSEC source: 0001628280-26-005487 · wk-form4_1770241082.xml · derivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:34 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 3,828 | $18.10 | $69,295.99 |
DisclosureSEC source: 0001628280-26-003419 · wk-form4_1769463288.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,164 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:52 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 149 | $18.02 | $2,684.98 |
DisclosureSEC source: 0001628280-26-002656 · wk-form4_1768945958.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,992 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:18 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001628280-25-059045 · wk-form4_1767046687.xml · derivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,909 Underlying: Common Stock · 25,000 shares Expires 2032-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following October 4, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:18 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 25,000 | $4.44 | $110,922.50 |
DisclosureSEC source: 0001628280-25-059045 · wk-form4_1767046687.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an ISO exercise and hold to acquire and retain direct share ownership of the issuer. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:52 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0002034665-25-000011 · wk-form4_1765921919.xml · derivative · entry 4 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,334 Underlying: Common Stock · 8,000 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:52 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 4,500 | $18.68 | $84,077.10 |
DisclosureSEC source: 0002034665-25-000011 · wk-form4_1765921919.xml · nonDerivative · entry 3 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,141 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.55 to $18.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:52 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 8,000 | $18.68 | $149,470.40 |
DisclosureSEC source: 0002034665-25-000011 · wk-form4_1765921919.xml · nonDerivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,641 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.55 to $18.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:52 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 8,000 | $3.79 | $30,318.40 |
DisclosureSEC source: 0002034665-25-000011 · wk-form4_1765921919.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 23:41 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0002034665-25-000009 · wk-form4_1764114091.xml · derivative · entry 4 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,334 Underlying: Common Stock · 8,000 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 23:41 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 4,500 | $18.05 | $81,211.50 |
DisclosureSEC source: 0002034665-25-000009 · wk-form4_1764114091.xml · nonDerivative · entry 3 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,641 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 23:41 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 8,000 | $18.05 | $144,376.00 |
DisclosureSEC source: 0002034665-25-000009 · wk-form4_1764114091.xml · nonDerivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,141 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 23:41 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 8,000 | $3.79 | $30,318.40 |
DisclosureSEC source: 0002034665-25-000009 · wk-form4_1764114091.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:41 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0002034665-25-000006 · wk-form4_1760647298.xml · derivative · entry 4 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,334 Underlying: Common Stock · 8,000 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:41 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 4,500 | $18.16 | $81,699.30 |
DisclosureSEC source: 0002034665-25-000006 · wk-form4_1760647298.xml · nonDerivative · entry 3 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,141 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:41 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 8,000 | $18.16 | $145,243.20 |
DisclosureSEC source: 0002034665-25-000006 · wk-form4_1760647298.xml · nonDerivative · entry 2 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,641 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:41 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 8,000 | $3.79 | $30,318.40 |
DisclosureSEC source: 0002034665-25-000006 · wk-form4_1760647298.xml · nonDerivative · entry 1 Cohlhepp Ryan · CIK 0002034665 · Director · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.